Company code: Hunan Warrant Pharmaceutical Co.Ltd(688799) company abbreviation: Hunan Warrant Pharmaceutical Co.Ltd(688799)
Hunan Warrant Pharmaceutical Co.Ltd(688799)
Notes on undisclosed internal control evaluation report in 2021
I Construction of internal control system
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of science and Innovation Board of Shanghai Stock Exchange and other relevant laws and regulations, the company has established systems and detailed rules that meet the normative requirements of corporate governance of listed companies.
In 2021, based on the external regulatory requirements and the actual situation of the company, the company revised the sub business modules of the internal control system and updated the relevant internal control management processes to ensure that the company’s internal control is compatible with the company’s business scale, business scope, competition and risk level. At the same time, the company actively guides all departments and units to carry out continuous self-supervision and inspection on the key control points in each business process, actively finds out the defects and deficiencies in the implementation process, and realizes the continuous improvement of internal control management. II Description of non disclosure of annual internal control evaluation report 1. Is there any special situation of non mandatory disclosure
√ yes □ no
Special circumstances of non mandatory disclosure are: New Listing 2. Description of specific circumstances
According to the reply on Approving the registration of Hunan Warrant Pharmaceutical Co.Ltd(688799) initial public offering (zjxk [2021] No. 1966) issued by China Securities Regulatory Commission (hereinafter referred to as “CSRC”) on June 8, 2021, the company was approved to issue 23.5 million shares to the public and was listed on the science and Innovation Board of Shanghai Stock Exchange on July 13, 2021.
According to Article 3 (II) of Chapter II of the business guide for information disclosure of listed companies on the science and Innovation Board No. 7 – matters related to annual reports: “a newly listed company shall start to build an internal control system in the year of listing, and disclose the internal control evaluation report and internal control audit report at the same time as the annual report of the next year of listing.” According to the above relevant provisions, the company is a newly listed company, so the internal control evaluation report of 2021 is not disclosed. The company will disclose the internal control evaluation report while disclosing the annual report of the next year.
Chairman (authorized by the board of directors): Huang Bendong Hunan Warrant Pharmaceutical Co.Ltd(688799) March 29, 2022
